Receive funding for your R&D Projects!
Your partner for subsidy advice
Your partner for subsidy advice
The measured decay properties match previous data, strengthening the case for official recognition of 117 as a new element. New findings obtained in the…
Scientists at the U.S. Department of Energy's Brookhaven National Laboratory are seeking ways to synchronize the magnetic spins in nanoscale devices to build…
In addition to the tropical storm warning, a typhoon watch is in effect for Alamagan and Pagan as Tapah is expected to continue in a generally northerly…
Siemens has installed the BorWin2 offshore platform in the North Sea northwest of the island of Borkum. This marks Siemens' achievement of the second crucial…
The team, the product of an ongoing collaboration between Professors W. Richard McCombie of Cold Spring Harbor Laboratory (CSHL) and Aiden Corvin of Trinity…
Several pathological conditions as autoimmune and inflammatory diseases are due to an excessive T cell activity. Treatment modalities are based on the relief from symptoms, whereby immune suppressive biologicals are rapidly expanding, owing to the good efficacy and safety profiles. However, for the regulation of the starting point of the disease-causing processes no agents exist until now. For that we offer a new agent with an exceptional stringent and specific suppression of T cell activation, whereby the inactivation is reversible. With this invention it is not only possible to address T cells in their entirety, but also antigen-specific T cells. Membrane mobility characteristics have not to be considered, because the target is located on the outside of T cells.